Chargement en cours...
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
BACKGROUND: Imatinib was the first BCR-ABL tyrosine kinase inhibitor (TKI) approved in the United States for the treatment of patients with chronic myelogenous leukemia and is currently the most prescribed TKI. The impending loss of patent exclusivity for imatinib has the potential to reduce costs f...
Enregistré dans:
| Publié dans: | Am Health Drug Benefits |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Engage Healthcare Communications, LLC
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4719136/ https://ncbi.nlm.nih.gov/pubmed/26834933 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|